# Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

> **NCT01923857** · PHASE1 · COMPLETED · sponsor: **Repros Therapeutics Inc.** · enrollment: 26 (actual)

## Conditions studied

- Secondary Hypogonadism

## Interventions

- **DRUG:** Androxal 25 mg

## Key facts

- **NCT ID:** NCT01923857
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2014-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01923857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01923857, "Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01923857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*